 |
9 Diseases |  |
32 Trials |
|
32 Trials |  |
751 News |  |
| 12345678910» |
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: Ten years of successful linaclotide treatment in a patient with intestinal pseudo-obstruction due to Ehlers-Danlos syndrome. (Pubmed Central) - Apr 23, 2024
No abstract available
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: cGMP-dependent kinase 2, Na+/H+ exchanger NHE3, and PDZ-adaptor NHERF2 co-assemble in apical membrane microdomains. (Pubmed Central) - Apr 17, 2024
NHE3, cGKII, and NHERF2 form a lipid raft-associated signal complex in the siBBM, which mediates the inhibition of salt and water absorption by Gucy2c activation. NHERF2 enhances the raft association of NHE3, which is essential for its close interaction with the exclusively raft-associated activated cGKII.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Preclinical, Journal: Renoprotective effects of laxative linaclotide: Inhibition of acute kidney injury and fibrosis in a rat model of renal ischemia-reperfusion. (Pubmed Central) - Apr 15, 2024
These findings suggest that linaclotide, with its established safety profile, could extend its benefits beyond gastrointestinal issues and potentially serve as a therapeutic intervention for organ transplantation. Additionally, it could provide immediate and practical insights into selecting laxatives for managing patients with AKI or CKD, regardless of the cause, and for those receiving dialysis or transplant therapy.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Resolor (prucalopride) / J&J, Takeda
Treatment patterns, barriers, and associated costs reported by patients with chronic idiopathic constipation in the United States: Analysis from a cross-sectional observational study () - Apr 9, 2024 - Abstract #AMCP2024AMCP_140;
The high- est out-of-pocket costs for patients were related to seeing an HCP and those associated with OTC and prescription medications. These factors may affect patient access to therapies for CIC.
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Clinical, Journal: Clinical trial: Randomized controlled trial of linaclotide in children aged 6-17 years with functional constipation. (Pubmed Central) - Mar 27, 2024
These factors may affect patient access to therapies for CIC. Linaclotide was well tolerated in this pediatric population, with a trend toward efficacy in the higher doses, warranting further evaluation.
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Clinical, Journal: Safety and efficacy of linaclotide in children aged 7-17 years with irritable bowel syndrome with constipation. (Pubmed Central) - Mar 24, 2024
Linaclotide was well tolerated in this pediatric population, with a trend toward efficacy in the higher doses, warranting further evaluation. Linaclotide was tolerated well in this pediatric population, showing numerical improvement in SBM frequency compared with placebo.
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion date, Trial primary completion date, Adverse events: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (clinicaltrials.gov) - Mar 15, 2024
P3, N=116, Recruiting, Sponsor: AbbVie
Linaclotide was tolerated well in this pediatric population, showing numerical improvement in SBM frequency compared with placebo. Trial completion date: Mar 2025 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Aug 2025
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Resolor (prucalopride) / J&J, Takeda
HORMONE REPLACEMENT THERAPY IS ASSOCIATED WITH INCREASED RISK OF DEVELOPING COLONIC AND ANORECTAL DYSMOTILITY IN POST-MENOPAUSAL WOMEN (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_7305;
Additionally, HRT is correlated with elevated gastrointestinal symptoms, augmented medication utilization, and heightened diagnostic testing. These findings underscore the importance of considering the potential consequences of HRT in post-menopausal women, particularly regarding colonic and anorectal dysmotility.
- Ibsrela (tenapanor) / Ardelyx
EFFICACY OF TENAPANOR IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C): A POST HOC ANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR USE OF OTHER IBS-C PRESCRIPTION MEDICATIONS FROM THE PHASE 3 T3MPO-1 AND T3MPO-2 STUDIES (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_7259;
Among patients with prior IBS-C prescription medication use, 42.3% (11 of 26) of patients responded to treatment with tenapanor compared to an 18.8% (6 of 32) response rate in the placebo arm ( P =0.038); among patients without prior use of IBS-C prescription medication, 31.5% (181 of 574) responded to treatment with tenapanor compared to a 21.7% (123 of 567) response rate in the placebo arm ( P <0.001) ( Table/Figure ). Conclusion In clinical trials, a clinically meaningful response to treatment with tenapanor among adults with IBS-C was observed regardless of prior IBS-C prescription medication use.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
EFFICACY, SAFETY, AND TIME TO RESPONSE OF LINACLOTIDE IN PATIENTS ?65 WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_7254;
P3, P3b
Increasing age does not appear to affect time to response. These findings emphasize that LIN represents a viable and safe treatment option for older individuals with IBS-C.
- IMPLICATIONS OF POPULAR TRENDING ANTI-OBESITY MEDICATIONS - AN INCREASE IN HEALTHCARE COST AND UTILIZATION FOR THE POPULATION WITH CONSTIPATION (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_6908;
These findings emphasize that LIN represents a viable and safe treatment option for older individuals with IBS-C. Inclusion criteria included obese patients started on an AOM (per the 2022 AGA Guideline on the Pharmacological Interventions for Adults with Obesity
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trikafta (elexacaftor/tezacaftor/ivacaftor) / Vertex
PARTIALLY DIFFERENTIATED ILEAL AND RECTAL HUMAN CFTR-F508DEL ENTEROIDS SECRETE FLUID IN RESPONSE TO CAMP AND CGMP (140AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4233;
CFTR F508del can be stimulated by cAMP and cGMP in PD enterocyte populations. Our findings identify a novel role of the partially differentiated ileal and rectal enterocyte populations which behave in a way that offers the potential to improve treatment for CF constipation.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Amitiza (lubiprostone) / Takeda, Mallinckrodt
ADDING SECRETAGOGUES TO LOW VOLUME PEG IMPROVES BOWEL PREPARATION WITHOUT INCREASING SIDE EFFECTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3512;
Only fully published randomized controlled trials (RCT) comparing Linaclotide and Lubiprostone in combination with PEG-based preps to other regimens in average-risk patients were included. Incorporating a secretagogue into low-volume PEG-based preparations is more likely to result in adequate and excellent bowel preparation compared to other PEG-based preparations, including low-volume 2L PEG-based solutions, and unlike other adjuncts, does not entail a significant increase in adverse events such as nausea or abdominal pain.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
REAL WORLD PRESCRIBING PATTERNS FOR PEDIATRIC PATIENTS WITH FUNCTIONAL CONSTIPATION AND IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3486;
Compared to FC, patients with IBS-C receiving PEG were more likely to receive another Rx, with docusate being the most common, followed by lactulose, linaclotide, and bisacodyl. All Rx use during the period covered in this analysis was off label for pediatric FC and IBS-C.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Resolor (prucalopride) / J&J, Takeda
DIFFERENCES IN PEDIATRIC CONSTIPATION PRACTICE PATTERNS BASED ON AN INTERNATIONAL SURVEY OF PEDIATRIC GASTROENTEROLOGISTS: DOES MARC THINK LIKE CARLO? (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3480;
Practice patterns differ widely among pediatric gastroenterologists in the evaluation and treatment of children with refractory FC. A clinical guideline regarding diagnostic testing and surgical decision-making is needed.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
DOES LINACLOTIDE HAVE HIGH PREDICTABILITY OF DEFECATION? A POST-HOC ANALYSIS OF APPLE TRIAL. (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_3175;
A single-dose of linaclotide had an early onset of defecation without reducing the patient tolerability compared to senna. It may be a promising treatment drug for constipation with high predictability.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
MULTICENTER STUDY TO EVALUATE THE EFFICACY OF 1-L ASCORBIC ACID PEG PLUS LINACLOTIDE FOR BOWEL PREPARATION: A RANDOMIZED, ENDOSCOPIST-BLINDED, CONTROLLED TRIAL (APPLE TRIAL) (143ABC - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2698;
The linaclotide regimen was superior to the senna regimen in terms of BP efficacy without reducing tolerability. It can be a new promising option for BP, especially in patients at high risk of inadequate BP.
- GLP-1 AGONISTS AND GIP PRESCRIPTIONS ARE INCREASING MORE THAN ANY OTHER GASTROINTESTINAL MEDICAITON AND CORRELATE WITH SIGNIFICANT INCREASE IN ASSOCIATED ADVERSE EVENTS (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_1374;
There was a 84% increase in GLP-1 and GLP-1/GIP from 2018 to 2023, greatest increase noted for semaglutide, liraglutide and tirzepatide (Figure 1 and 2). In comparison to PPI (15% increase), opioids (stable), famotidine (62% increase), dicyclomine (11% increase), linzess (67% increase), anti-nausea medications (28% increase), GLP-1 and GLP-1/GIP had the greatest increase in prescriptions over the past 6 years.
- RISK OF CONSTIPATION WITH ANTI-OBESITY MEDICATION AND CURRENT PRESCRIBING PATTERN LANDSCAPE IN MANAGING THE SIDE EFFECT (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_1364;
Black patients had higher rate of new constipation diagnosis and treatment compared to White patients. Semaglutide had the least risk for requiring constipation medication.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: The Effects of Combined Use of Linaclotide and Polyethylene Glycol Electrolyte Powder in Colonoscopy Preparation for Patients With Chronic Constipation. (Pubmed Central) - Mar 6, 2024
The 3L PEG+L is optimal among the 4 procedures. It can facilitate high-quality bowel preparation, reduce the incidence of nausea during the bowel preparation procedure, and encourage patients to undertake repeated bowel preparation.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion date, Trial primary completion date, Adverse events: A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide (clinicaltrials.gov) - Mar 5, 2024
P2, N=30, Recruiting, Sponsor: AbbVie
It can facilitate high-quality bowel preparation, reduce the incidence of nausea during the bowel preparation procedure, and encourage patients to undertake repeated bowel preparation. Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Apr 2024 --> Sep 2025
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
P3 data, Journal: Linaclotide for functional constipation in paediatric patients: phase III results. (Pubmed Central) - Mar 4, 2024
Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Apr 2024 --> Sep 2025 No abstract available
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion, Trial completion date, Trial primary completion date: Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy (clinicaltrials.gov) - Jan 16, 2024
P=N/A, N=1513, Completed, Sponsor: Changhai Hospital
No abstract available Recruiting --> Completed | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Aug 2023
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Review, Journal: Fundamental Neurochemistry Review: The role of enteroendocrine cells in visceral pain. (Pubmed Central) - Dec 22, 2023
While this brings some clarity to the relationship between linaclotide and visceral analgesia, questions remain about the intracellular signaling mechanisms and neurotransmitters mediating this communication. In this Fundamental Neurochemistry Review, we discuss what is currently known about visceral nociceptors, enteroendocrine cells, and the gut-brain axis, and ongoing areas of research regarding that axis and visceral pain.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
New trial: Effects of linaclotide combined with polyethylene glycol in bowel preparation for colonoscopic polypectomy: A randomized controlled trial. (EUDRACT) - Dec 5, 2023
P=N/A, N=422, Not yet recruiting, Sponsor: The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
In this Fundamental Neurochemistry Review, we discuss what is currently known about visceral nociceptors, enteroendocrine cells, and the gut-brain axis, and ongoing areas of research regarding that axis and visceral pain. .
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Preclinical, Journal: The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics. (Pubmed Central) - Nov 30, 2023
These altered properties are reflected in the high concentrations of ligands required to elicit signaling responses in the mouse gut in preclinical models and the specificity of a guanylyl cyclase inhibitor towards human GC-C. Therefore, our studies identify considerations in using the murine model to test molecules for therapeutic purposes that work as either agonists or antagonists of GC-C, and vaccines for the bacterial heat-stable enterotoxin that causes watery diarrhea in humans.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: Cost impact of incorporating linaclotide into low-volume colonoscopy preparation. (Pubmed Central) - Nov 3, 2023
Therefore, our studies identify considerations in using the murine model to test molecules for therapeutic purposes that work as either agonists or antagonists of GC-C, and vaccines for the bacterial heat-stable enterotoxin that causes watery diarrhea in humans. No abstract available
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Resolor (prucalopride) / J&J, Takeda, Amitiza (lubiprostone) / Takeda, Mallinckrodt
Review, Journal: Recommendations for the management of opioid-induced constipation - how to improve usability in clinical practice. (Pubmed Central) - Nov 3, 2023
It was validated in primary care for credibility, clarity, relevance, usability, and overall benefit. We believe that this initiative can lead to better management of the substantial proportion of patients suffering from side effects of opioids.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Guanylyl cyclase C is a potential therapeutic target to prevent neurodegeneration in Parkinson (WCC 144) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_689;
Our findings emphasize the translational potential of targeting neural GUCY2C with exogenous ligands to slow the rate of neurodegeneration in PD. In that context, GUCY2C ligands linaclotide (Linzess
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion date, Trial primary completion date: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (clinicaltrials.gov) - Nov 1, 2023
P3, N=426, Recruiting, Sponsor: Allergan
In that context, GUCY2C ligands linaclotide (Linzess Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion date, Trial primary completion date: Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C (clinicaltrials.gov) - Oct 30, 2023
P3, N=120, Enrolling by invitation, Sponsor: Allergan
Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024 Trial completion date: Jul 2024 --> Oct 2025 | Trial primary completion date: Jul 2024 --> Oct 2025
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion date, Trial primary completion date, Adverse events: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (clinicaltrials.gov) - Sep 28, 2023
P3, N=100, Recruiting, Sponsor: AbbVie
Trial completion date: Jul 2024 --> Oct 2025 | Trial primary completion date: Jul 2024 --> Oct 2025 Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Nov 2024
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: Bowel preparation efficacy and safety of compound polyethylene glycol electrolyte powder combined with linaclotide for colonoscopy: A randomized controlled trial. (Pubmed Central) - Sep 25, 2023
There was no statistically significant difference in the detection rate of colon polyps between each group. The quality of bowel preparation of the compound polyethylene glycol electrolyte powder combined with linaclotide is approximately the same as that of 4LPEG, and it can reduce the adverse reactions in the process of bowel preparation, and its intestinal cleansing effect is also better than that of 2LPEG.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: Microbiota-derived butyrate dampens linaclotide stimulation of the guanylate cyclase C pathway in patient-derived colonoids. (Pubmed Central) - Sep 22, 2023
Patient-derived colonoids demonstrate that microbiota-derived butyrate can dampen human colonic responses to linaclotide. This study supports incorporation of microbiota and metabolomic assessment to improve precision medicine for DGBI patients.
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: Linaclotide (Linzess) for functional constipation. (Pubmed Central) - Aug 31, 2023
This study supports incorporation of microbiota and metabolomic assessment to improve precision medicine for DGBI patients. No abstract available
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal, Real-world evidence, Real-world: Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data. (Pubmed Central) - Aug 18, 2023
Weight loss in patients prescribed semaglutide from real-world evidence was strong but attenuated compared with previous clinical trials. Machine-learning analysis of electronic health record data identified factors that warrant further research and consideration when tailoring weight-loss therapy.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Resolor (prucalopride) / J&J, Takeda
Sudden Onset Persistent Colonic Hypomotility After Laparoscopic Sleeve Gastrectomy (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3857;
Bariatric patients with colonic motility dysfunction after LSG should be identified and their pathophysiology should be further explored in order to limit procedure complications, reduce health care costs, and improve quality of life. Figure: Image 1: CT Showing Recurrent Significant Right-Sided Colonic Stool Burden
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Linaclotide Improves Abdominal Symptoms Over Placebo in Patients With Chronic Idiopathic Constipation: A Pooled Analysis (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3848;
P3, P3b
At 12 weeks, the LIN group had statistically significant decreases in CFB and %CFB for abdominal pain, discomfort, and bloating compared to PBO (all P < 0.0001) [ Figure A-B ]. Significant improvements in all 3 abdominal symptoms with LIN vs PBO were seen starting at week 1 and sustained through week 12 ( Figure C ).
- Prevalence and Choice of Pharmacologic Management of Functional Dyspepsia and Irritable Bowel Syndrome During Pregnancy (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2425;
17,984 of 48,208 IBSFD patients (37%) were exposed to proton pump inhibitors compared to 266,835 of 3,046,065 (9%) of NONE (OR 6.20; 95% CI 6.08 - 6.52). 1.4% of IBSFD were exposed to Rifaximin compared to 0.032% of NONE (OR 44.44; CI 40.19 - 49.14).
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Effect of Menopausal Status Defined by Age on Treatment Efficacy in Women With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis of Pooled Phase 2b/3 Trials (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1008;
Significant improvements in abdominal score (PBO group) and CSBM/week (LIN group) were observed in patients aged > 45 vs ? 45 years.
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Treatment Satisfaction and Quality of Life in Patients with Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_994;
Overall, the IBS-C (n = 910) and CIC (n = 2533) groups reported significantly worse scores than the control groups for PCS, MCS, and VR-6D. There were no significant differences in MCS compared to control in participants with IBS-C or CIC taking linaclotide who were satisfied with control of their bowel, abdominal, or both of their symptoms ( Table ).
- || Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial initiation date, Combination therapy: IBSC-VR: A Study of Virtual Reality and Linaclotide for IBS-C (clinicaltrials.gov) - Jul 28, 2023
P=N/A, N=65, Not yet recruiting, Sponsor: Mayo Clinic
There were no significant differences in MCS compared to control in participants with IBS-C or CIC taking linaclotide who were satisfied with control of their bowel, abdominal, or both of their symptoms ( Table ). Initiation date: Jun 2023 --> Sep 2023
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion, Trial primary completion date: Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation (clinicaltrials.gov) - Jul 20, 2023
P=N/A, N=800, Completed, Sponsor: Zhiguo Liu
Initiation date: Jun 2023 --> Sep 2023 Recruiting --> Completed | Trial primary completion date: Mar 2023 --> Jun 2023
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Clinical: 9/My Practice🧑🏻⚕️@ebgidoc 💎Assess for pelvic floor dysfunction and consider anorectal manometry/defecography 💎Gauge expectations with your patients 💎Inquire about Tx💊that failed 💎Choose an affordable Tx💊 💎Start linaclotide/plecanatide if👤failed PEG or other💊 (Twitter) - Jul 12, 2023
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Resolor (prucalopride) / J&J, Takeda
Clinical: 6/Results📊 Part 1: 🟢PEG🟰superior to placebo and strongly recommended for CIC 🟢Linaclotide, plecanatide & prucalopride🟰superior to placebo and strongly recommended AFTER OTC Tx failure👎🏻 *💪🏻=low/very low, 💪🏻💪🏻=moderate, 💪🏻💪🏻💪🏻=strong (Twitter) - Jul 12, 2023
- |||| Retrospective data, Review: 4/Design✏️ 💎Systematic review with meta-analysis assessing: 💊 🔸Fiber 🔸Osmotic laxatives: PEG, MgOx, lactulose 🔸Stimulant laxatives: bisacoyl, NaPicosulfate, senna 🔸Secretagogues: lubiprostone, linaclotide, plecanatide 🔸Serotonin type-4 agonist: prucalopride (Twitter) - Jul 12, 2023
- | Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: l-Methionine Selenoxide as an Oxidizing and Deprotection Reagent for the Synthesis of Multiple Disulfide Bonds in Peptides. (Pubmed Central) - Jul 10, 2023
The mechanistic picture for the SeODR approach was delineated, in which the formation of a stable Se-X-S bridge as the transition state plays a critical role. The SeODR approach was also utilized to construct the three disulfide bonds in linaclotide, conferring a reasonable yield.
- ||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Amitiza (lubiprostone) / Takeda, Mallinckrodt
Clinical guideline, Review, Journal: 2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation. (Pubmed Central) - Jul 7, 2023
The guidelines consist of 34 recommendations, including 3 concerning the definition and epidemiology of functional constipation, 9 regarding diagnoses, and 22 regarding managements. Clinicians (including primary physicians, general health professionals, medical students, residents, and other healthcare professionals) and patients can refer to these guidelines to make informed decisions regarding the management of functional constipation.
- |||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial primary completion date: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (clinicaltrials.gov) - Jun 29, 2023
P3, N=426, Recruiting, Sponsor: Allergan
Clinicians (including primary physicians, general health professionals, medical students, residents, and other healthcare professionals) and patients can refer to these guidelines to make informed decisions regarding the management of functional constipation. Trial primary completion date: Jul 2023 --> Mar 2024
- ||| Clinical guideline, Journal: American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. (Pubmed Central) - Jun 2, 2023
The guidelines are meant to provide a framework for approaching the management of CIC; clinical providers should engage in shared decision making based on patient preferences as well as medication cost and availability. Limitations and gaps in the evidence are highlighted to help guide future research opportunities and enhance the care of patients with chronic constipation.